Efficacy and safety of long-acting injectable risperidone in patients with schizophrenia
CHEN Yun-chun
TAN Qing-rong
WANG Huai-hai
ZHANG Rui-guo
WANG Hua-ning
WANG Zhi-zhong
GUO Li
Abstract：Objective:To assess the efficacy and safety of long-acting injectable risperidone(LAIR) in patients with schizophrenia.Methods:A total of 48 schizophrenia patients with symptoms lasting over 1 year were collected,and treated with LAIR and oral risperidone tablets for 4 weeks followed by LAIR alone for 8 weeks.The efficacy was evaluated using the Positive and Negative Syndrome Scale(PANSS),Clinical Global Impression Scales for severity(CGI-S) and Personal and Social Performance Scale(PSP).The adverse reactions were evaluated using the TESS,AIMS,BARS Scale,laboratory indexes,vital signs,medical and electrocardiographic examinations.Results:After treatment with LAIR alone for 8 weeks,the total effective rate(PANSS reduced ≥30%)was 80.5% ;mean reduction in CGI-S was 2.1 ;the rate of patients with increased PSP ≥7 was 85.32%.LAIR mildly affected weight-gain profile and caused less extrapyramidal reactions.There were no significant changes in vital signs,medical and electrocardiographic examinations,but 7.0% patients had an increase in glutamate pyruvate transaminase(GPT) activity.Conclusions:LAIR significantly improves the social performance in patients with schizophrenia,and can be used as the first line antipsyehotie for monotherapy.
Keywords：schizophrenialong-acting injectable risperidoneatypical antipsychotieefficacysafety
Publication Date：2010-01-01
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：4( 399-402 )